Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial
Top Cited Papers
- 1 August 2013
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 14 (9) , 823-833
- https://doi.org/10.1016/s1470-2045(13)70274-2
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Application of Novel Response/Progression Measures for Surgically Delivered Therapies for GliomasNeurosurgery, 2012
- An extent of resection threshold for newly diagnosed glioblastomasJournal of Neurosurgery, 2011
- Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastomaNeuro-Oncology, 2010
- End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's CriteriaJournal of Clinical Oncology, 2009
- Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in GliomaThe Journal of Molecular Diagnostics, 2008
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Adenovirus Binding to the Coxsackievirus and Adenovirus Receptor or Integrins Is Not Required To Elicit Brain Inflammation but Is Necessary To Transduce Specific Neural Cell TypesJournal of Virology, 2002
- Preferential transduction of neurons by canine adenovirus vectors and their efficient retrograde transport in vivoThe FASEB Journal, 2001
- β-Galactosidase Gene Transfer to Human Malignant Glioma In Vivo Using Replication-Deficient Retroviruses and AdenovirusesHuman Gene Therapy, 1998
- In VitroEvidence That Metabolic Cooperation Is Responsible for the Bystander Effect Observed with HSVtkRetroviral Gene TherapyHuman Gene Therapy, 1993